Ocumetics Raises Capital for Clinical Trials

Ocumetics Technology Corp (TSE:OTC) has released an update.

Ocumetics Technology Corp has launched a private placement of secured convertible debentures to raise up to $4 million, with a notable 18% annual interest rate and a two-year maturity. The principal is convertible into common shares at $0.32 each, aimed at funding the company’s pioneering human clinical trials and ongoing R&D. This move signals Ocumetics’ commitment to advancing its adaptive lens technology in the ophthalmic industry.

For further insights into TSE:OTC stock, check out TipRanks’ Stock Analysis page.